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Background: Cellular differentiation is characterized by the acquisition of specialized structures and functions, cell
cycle exit, and global attenuation of the DNA damage response. It is largely unknown how these diverse cellular
events are coordinated at the molecular level during differentiation. We addressed this question in a model system
of neuroblastoma cell differentiation induced by HOXC9.
Results: We conducted a genome-wide analysis of the HOXC9-induced neuronal differentiation program. Microarray
gene expression profiling revealed that HOXC9-induced differentiation was associated with transcriptional regulation of
2,370 genes, characterized by global upregulation of neuronal genes and downregulation of cell cycle and DNA repair
genes. Remarkably, genome-wide mapping by ChIP-seq demonstrated that HOXC9 bound to 40% of these genes,
including a large number of genes involved in neuronal differentiation, cell cycle progression and the DNA damage
response. Moreover, we showed that HOXC9 interacted with the transcriptional repressor E2F6 and recruited it to the
promoters of cell cycle genes for repressing their expression.
Conclusions: Our results demonstrate that HOXC9 coordinates diverse cellular processes associated with
differentiation by directly activating and repressing the transcription of distinct sets of genes.
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Cellular differentiation is an essential process of normal
development by which a stem or progenitor cell becomes
a post-mitotic, specialized cell with unique morphology
and function. In addition, it has long been recognized that
differentiated cells of both normal and tumor origin are
defective in the DNA damage response and repair at the
global level, displaying a marked increase in sensitivity to
ionizing radiation and other DNA damaging agents [1-3].
Consistent with these observations, recent studies have
shown that brain and breast cancer stem cells, a small* Correspondence: hcui@swu.edu.cn; hding@gru.edu
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reproduction in any medium, provided the orsubpopulation of tumor cells thought to be responsible for
initiating and sustaining tumor growth [4-6], are more
resistant to irradiation and chemotherapy than bulk tumor
cells [7-10]. Particularly interesting is the observation that
inhibition of DNA damage checkpoint kinases can reverse
the radioresistance of glioma stem cells [7]. Thus, a
molecular understanding of cellular differentiation may
suggest new therapeutic strategies that target both cell
proliferation and the DNA damage response.
Among the genes that have a critical role in the control of
cellular differentiation are the HOX gene family members.
HOX genes encode a family of transcription factors that
function as master regulators of morphogenesis and cell fate
specification [11-13]. Dysregulation of HOX gene expression
has been implicated in the pathogenesis of cancers of differ-
ent tissue types. In most tumor types, HOX genes function
as oncogenes to promote cancer development such astd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cancers [13,14]. However, in neuroblastoma, a common
childhood malignant tumor of the sympathetic nervous
system [15,16], there is evidence suggesting that HOX genes
may function as tumor suppressors [13]. Particularly, down-
regulation of HOXC9 expression is significantly associated
with poor prognosis in neuroblastoma patients [17,18].
Neuroblastoma cells can be induced to undergo neuronal
differentiation by serum deprivation [19], nerve growth
factor [20] or retinoic acid (RA) [21]. RA-induced neuronal
differentiation of neuroblastoma cells is a well-established
model for molecular investigation of neuronal differenti-
ation [22]. We recently reported that RA-induced differenti-
ation of neuroblastoma cells required the activation of
several HOX genes [18,23]. Among them, HOXC9 appeared
to be a major mediator of RA action in neuroblastoma cells.
HOXC9 expression was upregulated by RA, and silencing
HOXC9 expression conferred resistance to RA-induced dif-
ferentiation. Importantly, ectopic HOXC9 expression alone
was sufficient to induce growth arrest and morphologic dif-
ferentiation in neuroblastoma cells, fully recapitulating the
neuronal differentiation phenotype induced by RA [18].
Differentiated neuroblastoma cells morphologically and
functionally resemble mature peripheral neurons charac-
terized by G1 arrest, extensive neurite outgrowth, and sig-
nificant resting potential. It has long been observed that
differentiated neuroblastoma cells are highly sensitive to
UV and X-ray radiation with a significantly reduced rate
of DNA damage repair [20,24-27]. The molecular basis for
the differentiation-induced radiosensitivity is not well
understood. The biological functions of RA are mediated
by multiple isotypes of RA receptors (RARs) and retinoid
X receptors (RXRs), which form RAR/RXR heterodimers
that bind RA response elements in the regulatory regions
of RA target genes and regulate their transcription [28].
The complexity of multiple RARs and RXRs involved in
the action of RA presents a daunting challenge to dissect
the molecular mechanism that coordinates the diverse
cellular events associated with differentiation. Thus,
the finding that HOXC9 alone is able to initiate a robust
transcriptional program that drives neuronal differentiation
provides a unique experimental system for this investiga-
tion. In this study, we conducted genome-wide profiling of
the HOXC9-initiated transcriptional program. Our investi-
gation reveals that HOXC9 directly regulates the expression
of three major sets of genes that separately control neur-
onal differentiation, cell cycle progression, and the DNA
damage response.
Results
Gene expression profiling of HOXC9-induced neuronal
differentiation
To gain a molecular understanding of HOXC9-induced
differentiation, we conducted microarray gene expressionprofiling of human neuroblastoma BE(2)-C/Tet-Off/myc-
HOXC9 cells, which express myc-tagged human HOXC9
and undergo neuronal differentiation in the absence of
doxycycline [18] (Figure 1A). The profiling analysis identi-
fied a total of 2,370 genes that were differentially expressed
(≥ +1.5 and ≤ −1.5 fold, P <0.01), with 879 genes being up-
regulated and 1,491 genes downregulated (Additional file 1:
Table S1). Gene annotation enrichment analysis revealed
that HOXC9-induced differentiation is characterized by a
genome-wide coordination in transcriptional regulation of
genes that control neuronal differentiation, cell cycle
progression, and the DNA damage response.
Global upregulation of neuronal genes
Gene Ontology (GO) analysis of the 879 HOXC9-
upregulated genes by DAVID [29,30] revealed that they
were significantly enriched for genes that control nervous
system development such as neuron generation and dif-
ferentiation, axonogenesis, and synapse formation and
organization (Figure 1B and Additional file 2: Table S2, en-
richment fold ≥ 2.0, false discovery rate (FDR) ≤1%). A total
of 105 HOXC9-responsive genes were involved in nervous
system development (Figure 1B), accounting for approxi-
mately 12% of the 879 genes upregulated by HOXC9. We
obtained similar results with Gene Set Enrichment Analysis
(GSEA), which showed significant enrichment of gene
sets involved in synaptogenesis and neuron differentiation
among the genes upregulated by HOXC9 (Figure 1C). Par-
ticularly significant was the activation of ASCL1, GFRA3,
RET, and NTN3 (Figure 1D). ASCL1, a member of the basic
helix-loop-helix (bHLH) family of transcription factors, is a
master regulator in the generation and differentiation of
sympathetic neurons [31,32]. GFRA3 encodes the glial cell
line-derived neurotrophic factor (GDNF) family receptor
alpha 3 (GFRα3), which forms a receptor complex with
RET that preferentially binds the GDNF family ligand Arte-
min. This receptor signaling has a critical role in embryonic
development of the sympathetic nervous system, promoting
the survival, differentiation, axonal outgrowth, and target
innervation of sympathetic neurons [33]. NTN3 (netrin 3)
belongs to a family of extracellular proteins that promote
axon growth and migration during the development of the
nervous system [34]. Ingenuity Pathways Analysis (IPA)
further revealed a network of HOXC9-upregulated genes
relevant to the development and function of sympathetic
neurons (Additional file 3: Figure S1). Together, these ana-
lyses demonstrate that HOXC9 activates a large number
of neuronal genes, providing the molecular mechanism
for its ability to induce neuronal differentiation of neuro-
blastoma cells.
Global downregulation of cell cycle and DNA repair genes
GO analysis of the 1,491 HOXC9-downregulated genes
revealed that they were remarkably enriched for genes
Figure 1 (See legend on next page.)
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Figure 1 Global upregulation of neuronal genes by HOXC9. (A) Schematic of experiment. Doxy, doxycycline. (B) DAVID analysis of
upregulated HOXC9-responsive genes for enriched GO biological process categories (enrichment fold > 2.0; FDR <1%). The number of genes for
each biological process category is indicated. (C) GSEA showing significant enrichment of gene sets involved in synapse organization and biogenesis
and neuron differentiation among the genes upregulated by HOXC9. (D) Heatmap of select neuronal genes activated by HOXC9.
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response (Figure 2A and Additional file 4: Table S3,
enrichment fold ≥ 2.0; FDR ≤1%). The analysis identified
206 genes involved in cell cycle regulation and 98 genes
in the DNA damage response (Figure 2A). Similarly,
GSEA showed that among the genes downregulated by
HOXC9, those regulating mitotic cell cycle, DNA rep-
lication and DNA repair were significantly enriched
(Figure 2B). IPA further revealed that the downregulated
genes include most of cyclin (CCN) and cyclin-dependent
kinase (CDK) genes, and genes that control DNA rep-
lication, mitosis, double-strand break (DSB) repair,
base excision repair (BER), nucleotide excision repair
(NER), mismatch repair (MMR), and Fanconi anemia
(FA)-mediated repair (Additional file 3: Figures S2A-S2E
and Additional file 4: Table S3). These findings suggest
that global downregulation of cell cycle and DNA repair
genes is the primary cause of the cell cycle arrest and
attenuation of the DNA damage response associated with
neuronal differentiation.
Genome-wide mapping of HOXC9-binding sites
We next asked how HOXC9 coordinates the expression
of distinct sets of genes: the upregulation of genes critical
for nervous system development and the downregulation
of genes essential for cell cycle progression and the DNA
damage response. Mechanistically, HOXC9 could function
through a few master transcription factors, which in
turn regulate their own subsets of target genes that
work together to drive differentiation. Alternatively,
HOXC9 could directly regulate distinct sets of genes to
coordinate the cellular events associated with differentiation.
To test these models, we conducted two independent
anti-HOXC9 chromatin immunoprecipitation assays
followed by massively parallel sequencing of the enriched
DNA fragments (ChIP-seq) for genome-wide mapping of
HOXC9-binding sites. We identified a total of 29,221
HOXC9-binding peaks with FDR less than 1% (Figure 3A
and Additional file 5: Table S4). Scatter plot analysis
(Figure 3B, R = 0.93, correlation coefficient) and ChIP-seq
tag profiles (Figure 3C) demonstrated that the mapping data
were highly reproducible between the two independent
HOXC9 ChIP-seq samples. We next analyzed the distribu-
tion of HOXC9-binding peaks within the genome that was
classified into functional categories including promoters
(within 5 kb upstream of the transcription start site, TSS),
5’-untranslated regions (5’-UTRs), exons, introns, 3’-UTRs,downstream (within 5-kb downstream of the gene),
and intergenic regions (outside −5 ~ +5 kb of genes). The
analysis revealed that a majority of HOXC9-binding peaks
were localized in introns (41.2%) and intergenic regions
(43.4%) (Figure 3D). However, after normalization to the
size of these functional regions, it became clear that
HOXC9-binding peaks were highly enriched in gene
promoters and 5’-UTRs (Figure 3E and F). Analysis of
the sequences covered by HOXC9-binding peaks with the
motif-finding program MEME revealed that the most
enriched binding motif (T/ATTTAT, E value = 1.6e-35)
corresponds to the Drosophila Abd-B motif (MA0165.1,
Figure 3G) and is highly homologous to the mouse
Hoxc9-binding motif (ATTTAT) [35]. HOXC9 is a
mammalian ortholog of the Drosophila Hox protein
Abd-B. Thus, myc-tagged HOXC9 binds to cognate
sequences in human neuroblastoma cells.
Genome-wide identification of HOXC9 target genes
The ChIP-seq assay revealed that a total of 4,992 genes
contained at least one HOXC9-binding peak within 5-kb
upstream or downstream of their genomic loci (Figure 3A
and Additional file 6: Table S5). We next combined the
anti-HOXC9 ChIP-seq data with the HOXC9 microarray
data to generate a list of genes that were bound by HOXC9
and whose expression levels were significantly changed as
a result of HOXC9 induction (≥ +1.5 and ≤ −1.5 fold,
P <0.01). The analysis revealed that 954 genes or 40.3% of
the 2,370 HOXC9-responsive genes are direct targets of
HOXC9, with 445 and 509 genes being upregulated and
downregulated, respectively (Additional file 7: Table S6).
GO analysis of HOXC9 direct target genes revealed a
transcriptional program characterized by coordinated
regulation of genes critical for neuron differentiation,
cell cycle progression, and the DNA damage response.
HOXC9 directly induces a large number of
neuronal genes
The only sets of genes that were significantly enriched
among the upregulated HOXC9 direct target genes are
those exclusively involved in nervous system develop-
ment, particularly the generation and differentiation of
neurons and axonogenesis (Figure 4A and Additional file 8:
Table S7, enrichment fold ≥ 2.0, FDR ≤ 5%). The 57
HOXC9 direct target genes account for 54.3% (57/105) of
the HOXC9-responsive genes involved in nervous sys-
tem development (Figure 1B). Among them are ASCL1,
Figure 2 Global downregulation of cell cycle and DNA repair genes by HOXC9. (A) DAVID analysis of downregulated HOXC9-responsive
genes for enriched GO biological process categories (enrichment fold > 2.0; FDR <1%). The number of genes for each biological process category
is indicated. (B) GSEA showing significant enrichment of gene sets involved in mitotic cell cycle, DNA replication and DNA repair among the
genes downregulated by HOXC9.
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seq tag profiles of HOXC9 binding to the promoter re-
gions of GFRA3, RET, and NTN3. As discussed above,
these genes have a critical role in sympathetic neuro-
genesis and axonogenesis.HOXC9 directly represses a large number of genes
essential for cell cycle progression and the DNA damage
response
GO analysis of the downregulated HOXC9 direct target
genes revealed that they were significantly enriched for
Figure 3 ChIP-seq analysis of HOXC9 genomic distribution. (A) Summary of HOXC9-binding peaks and genes identified by ChIP-seq. (B-C)
Scatter plot analysis (B) and ChIP-seq tag profiles of chromosome 21 (C) showing a high correlation between two independent HOXC9 ChIP-seq
samples. (D) Pie chart showing genomic distribution of HOXC9-binding peaks relative to RefSeq functional categories including promoters (within
5 kb upstream of TSS), 5’ UTRs, exons, introns, 3’ UTRs, downstream (within 5 kb downstream of the gene), and intergenic regions (outside −5 ~ +5 kb
of genes). (E) Bar graph showing the distribution of HOXC9-binding peaks relative to the functional categories after normalization to the size of each
category in 100 kb. (F) Histogram showing the distribution of HOXC9-binding peaks relative to the nearest TSS. Peaks were combined in 100 bp.
(G) Web logo showing the top enriched motif present in HOXC9 ChIP-seq peaks, which corresponds to the binding site for Abd-B, the Drosophila
ortholog of mammalian HOX9-13 paralogs.
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DNA damage response (Figure 5A and Additional file 9:
Table S8), enrichment fold ≥ 2.0, FDR ≤ 1%). The analysis
identified 52 cell cycle genes that were directly repressed
by HOXC9 (Figure 5A), accounting for 25.2% (52/206) of
the HOXC9-responsive genes involved in cell cycle
regulation (Figure 2A). It was particularly striking that
the vast majority of the HOXC9-repressed cell cycle
genes are involved in the control of the M phase (n = 25)
and DNA replication (n = 21) (Figure 5A). Figure 5B and
C show the association of HOXC9 with the promoter
regions of representative cell cycle genes, including
CDC45L and MCM3 (DNA replication), and CCNB1 and
CDCA8 (M phase). CDC45L and MCM3 are components
of the replicative complex that catalyzes DNA replication
during the S phase [36], while CDCA8, also known as
BOREALIN, is a component of the chromosomal passenger
complex essential for mitosis and cell division [37].
We also identified 32 genes associated with the DNA
damage response that were directly repressed by HOXC9(Figure 5A), accounting for 32.7% (32/98) of the
HOXC9-responsive genes involved in the DNA damage
response. Figure 5D shows the binding of HOXC9 to the
promoter of FANCM and to both the promoter and
3’ region of FEN1. FANCM is a component of the
FANCM–FAAP24–MHF protein complex that binds
to DNA with interstrand cross-links and is responsible for
recruiting the FA core complex to the damaged site [38].
FEN1 (flap endonuclease 1) is essential for DNA replication
and repair by removing RNA and DNA 5' flaps [39].
Collectively, these findings suggest that HOXC9 directly
regulates the expression of distinct sets of genes to coord-
inate the molecular and cellular processes characteristic of
neuronal differentiation.
HOXC9 targets E2F6 to the promoters of cell cycle genes
We next sought to determine the molecular basis for
HOXC9 regulation of gene expression by identifying
HOXC9-interacting proteins. We used a myc-tag antibody
to isolate myc-HOXC9 and its associated proteins from
Figure 4 HOXC9 directly induces a large number of neuronal genes. (A) DAVID analysis of upregulated HOXC9 target genes for enriched
GO biological process categories (enrichment fold > 2.0; FDR < 5%). The number of genes for each biological process category is indicated.
(B) ChIP-seq tag profiles showing HOXC9 binding to representative upregulated HOXC9 target genes involved in nervous system development
(GFRA3, top; RET, middle; NTN3, bottom).
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tured in the absence of doxycycline for 6 days (Additional
file 3: Figure S3A). Mass spectrometric analysis of two
independent samples identified E2F6 as a HOXC9-interacting protein (Additional file 3: Figure S3B), a well
characterized transcriptional repressor that plays a major
role in repressing E2F-responsive genes essential for cell
proliferation [40]. It is known that E2F family proteins
Figure 5 HOXC9 directly represses a large number of cell cycle and DNA repair genes. (A) DAVID analysis of downregulated HOXC9 target
genes for enriched GO biological process categories (enrichment fold > 2.0; FDR <1%). The number of genes for each biological process category is
indicated. (B-D) ChIP-seq tag profiles showing HOXC9 binding to representative downregulated HOXC9 target genes involved in DNA replication
(B), mitosis (C), and DNA repair (D).
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binding site [41]. Interestingly, GSEA revealed significant
enrichment of the E2F-binding motif among the genes
downregulated by HOXC9 (Additional file 3: Figure S3C).
Taken together, these observations suggest that E2F6 has
an important role in HOXC9-mediated repression of cell
cycle genes.
To corroborate the finding of mass spectrometry, we
performed co-immunoprecipitation (Co-IP) experiments
using nuclear extracts from BE(2)-C/Tet-Off/myc-HOXC9
cells cultured in the absence of doxycycline for 6 days.
The myc-tag antibody, but not control IgG, precipitated
myc-HOXC9 and E2F6 (Figure 6A, left panel). Reciprocally,an E2F6 antibody precipitated E2F6 and myc-HOXC9
(Figure 6A, right panel). We next performed size-exclusion
chromatography using the same nuclear extracts. Immuno-
blot analysis revealed the presence of HOXC9 (~31 kDa) in
two complexes: the larger complex (peak at fraction 20)
had an estimated molecular mass of ~1,800 kDa and the
other (peak at fraction 34) of ~250 kDa (Figure 6B). A
significant amount of endogenous E2F6 (~36 kDa) co-eluted
with the 1,800-kDa HOXC9 complex, whereas MEIS2
(~37-49 kDa), which interacts with HOX proteins and
functions as a HOX cofactor [12], exclusively co-eluted
with the 250 kDa-HOXC9 complex (Figure 6B). Co-IP ex-
periments using pooled fractions confirmed the association
Figure 6 HOXC9 interacts with E2F6 and recruits it to cell cycle genes. (A) Reciprocal Co-IP of myc-HOXC9 and E2F6 in nuclear extracts
from BE(2)-C/Tet-Off/myc-HOXC9 cells cultured in the absence of doxycycline (Doxy) for 6 days. (B) Size-exclusion chromatography analysis of
complexes containing myc-HOXC9, E2F6 or MEIS2 in nuclear extracts of BE(2)-C/Tet-Off/myc-HOXC9 cells cultured in the absence of Doxy for
6 days. (C) Co-IP of myc-HOXC9 and E2F6 in pooled Superose-6 fractions 19–21. (D) ChIP-qPCR analysis showing E2F6 binding to specific promoter
regions of the cell cycle genes CCNB1 and CDCA8 in BE(2)-C/Tet-Off/myc-HOXC9 cells before (Doxy+) and after (Doxy-) HOXC9 induction. Dashed lines
indicate IgG control. Error bars represent SD (n = 3). Data were analyzed with unpaired, two-tailed Student’s t-test and p values are indicated.
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(Figure 6C).
To determine whether the HOXC9-E2F6 interaction
plays a role in recruiting E2F6 to HOXC9 target genes
in vivo, we performed anti-E2F6 ChIP using BE(2)-C/
Tet-Off/myc-HOXC9 cells before and after HOXC9 induc-
tion. HOXC9 induction had no apparent effect on E2F6
expression as determined by microarray gene expression
profiling (−1.003 fold). ChIP-qPCR assay revealed that
E2F6 was recruited to specific promoter regions of the
cell cycle genes CCNB1 and CDCA8 only after HOXC9
induction (Figure 6D). By contrast, no significant binding
of E2F6 to the NEFM promoter was observed before andafter HOXC9 induction (Additional file 3: Figure S4A). As
reported previously, NEFM is a neuronal gene directly
activated by HOXC9 during differentiation [18] (See also
Additional file 3: Figure S4B). Together, these data suggest
that elevated levels of HOXC9 facilitate the formation of a
repressive complex with E2F6, which is then recruited to
cell cycle but not neuronal genes during differentiation.
E2F6 is essential for HOXC9-induced cell cycle arrest and
transcriptional repression of cell cycle genes
To determine the functional significance of the HOXC9-
E2F6 interaction, we examined the effect of E2F6
knockdown on HOXC9-induced growth arrest. We
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targeting different coding regions of the human E2F6 gene
(Figure 7A). Cells with E2F6 knockdown were highly
resistant to HOXC9-induced G1 arrest, showing continued
cell proliferation (Figure 7B) and cell cycle progression
(Figure 7C) following HOXC9 induction. This was accom-
panied by a marked decrease in the population of cells in
the G1 phase and a significant increase in the population
of cells in the S phase (Figure 7D). In addition, E2F6
knockdown largely abrogated the ability of HOXC9 to
repress cyclin A2 and B1 expression, but had no significant
effect on HOXC9 induction of NEFM (Figure 7E and F), a
finding consistent with the observation of no significant
E2F6 binding to the NEFM promoter during HOXC9-
induced differentiation (Additional file 3: Figure S4A).
Together, these findings identify an essential and specific
role for E2F6 in HOXC9 induction of growth arrest and
repression of cell cycle genes.
Discussion
In this report, we present evidence for a master regulator
of development with the capacity to coordinate diverse
cellular events characteristic of neuronal differentiation by
simultaneously and directly regulating distinct sets of
genes (Figure 8). Through gene expression profiling, we
show that HOXC9-induced neuronal differentiation is
characterized at the molecular level by transcriptional
regulation of 2,370 genes, with global activation of genes
that promote nervous system development and repression
of genes that are essential for cell cycle progression and
the DNA damage response. Moreover, through a combin-
ation of genome-wide mapping of HOXC9 binding sites
and gene expression profiling, we show that HOXC9
directly regulates the expression of 954 genes, ~40% of the
2,370 HOXC9-responsive genes, including a large number
of genes required for neuronal differentiation, cell cycle
progression and the DNA damage response. Finally, we
identify an essential role for E2F6 in HOXC9 repression of
cell cycle genes and induction of G1 arrest.
Our findings that HOXC9 can both activate and
repress gene transcription are consistent with previous
observations from the study of spinal cord development in
chick and mouse embryos. In the developing spinal cord,
Hoxc9 functions as a transcription activator to promote the
fate of preganglionic motor column (PGC) neurons [42],
most likely through its interaction with the transcription
factor FoxP1 [43,44]. However, Hoxc9 can also specify
the fate of hypaxial motor column (HMC) neurons by
repressing the Hox genes that promote the switch of
HMC neurons to the lateral motor column (LMC) neurons
[35]. Importantly, our study further demonstrated that
within the same population of neuroblastoma cells, HOXC9
could simultaneously activate the genes that promote neur-
onal differentiation and repress the genes that are essentialfor cell cycle progression and the DNA damage response.
While the molecular basis for the transcription activator
function of HOXC9 in neuroblastoma cells remain to be
defined, we showed that the ability of HOXC9 to repress
cell cycle genes depended on its interaction with the
transcription repressor E2F6, a member of the E2F family
of transcription factors that have a critical role in the
control of cell proliferation [40].
Cellular differentiation is tightly linked to cell cycle
exit, with the differentiated cell containing the G1 content
of DNA. The molecular mechanism that couples cell cycle
exit and differentiation is not well understood, although it
is generally recognized that cell cycle regulators influence
differentiation, and cell fate determinants influence the
cell cycle [45-48]. A primary example is the CDK inhibitor
p27Kip1 as a key regulator that links cell cycle exit
and differentiation during development. p27Kip1 induces
G1 arrest by associating with CDK/cyclin complexes and
inhibits their kinase activity [49]. Overexpression of
p27Xic1, a Xenopus homolog of p27Kip1, in Xenopus retina
glial progenitor cells promotes both cell cycle exit and
differentiation [50]. Knockout and overexpression studies
also demonstrate an important role of p27Kip1 in neuronal
differentiation in the mouse cerebral cortex by stabilizing
Neurogenin 2 [51], a proneural bHLH transcription factor
with a central role in cortical neurogenesis [52]. On the
other hand, cell fate determinants can also modulate the
expression of p27Kip1 for coordinated regulation of cell
cycle exit and differentiation. For instance, Drosophila
proneural bHLH proteins cooperate with epidermal
growth factor signaling to directly activate the transcrip-
tion of Dapaco, a homolog of p21Cip/p27Kip1, during the
differentiation of photoreceptor cells [53].
Our findings suggest an alternative mechanism for
coupling cell cycle exit and differentiation. HOXC9 does
not regulate the expression of CDK inhibitors, including
p27Kip1 and p21Cip, and overexpression of either p27Kip1
or p21Cip fails to stop the proliferation of BE(2)-C cells
[18]. Rather, HOXC9 induces G1 arrest by directly
repressing a large number of genes essential for cell cycle
progression through the S to M phases, including cyclin
B1, CDCA3, CDCA8, BUB1B, MCM3 and MCM8. This
transcriptional repression function of HOXC9 requires
E2F6. We found that HOXC9 interacts with E2F6 and
recruits it specifically to the promoters of cell cycle genes.
E2F6 lacks a transactivation domain and functions as
a transcriptional repressor for E2F-responsive genes
that drive cell proliferation [54-58]. Mechanistically, E2F6
interacts with chromatin modifiers with transcription re-
pressor activity to establish a repressive chromatin structure.
These chromatin modifiers include the DNA methyltrans-
ferase Dnmt3b [59] and polycomb-group (PcG) proteins
[60-63]. In our study, we identified HOXC9 and E2F6
within a complex of approximately 1,800 kDa. Whether this
Figure 7 E2F6 is essential for HOXC9 induction of G1 arrest and repression of cell cycle genes. (A) Immunoblot analysis of E2F6 levels in
BE(2)-C/Tet-Off/myc-HOXC9 cells infected with lentiviruses expressing shRNA against GFP or various coding regions of E2F6. E2F6 levels were
quantified against β-actin. (B-D) Phase contrast imaging and growth assay (B) and cell cycle analysis (C, D) showing E2F6 knockdown abrogated
HOXC9-induced growth arrest. Error bars, SD (n = 4). (E-F) Immunoblot analysis (E) and quantification (F) showing that E2F6 knockdown abrogated
HOXC9 repression of cyclins, but not HOXC9 induction of NEFM. HOXC9, CCNA2, CCNB1 and NEFM levels were quantified against β-actin with the
protein levels in GFPsh-expressing cells cultured in the presence of doxycycline (Doxy+) were defined as 1.0 (dashed lines). Error bars, SD (n = 3).
Data in (D) and (F) were analyzed with unpaired, two-tailed Student’s t-test and p values are indicated.
Wang et al. BMC Genomics 2013, 14:830 Page 11 of 16
http://www.biomedcentral.com/1471-2164/14/830
Figure 8 HOXC9 directly regulates the expression of distinct
sets of genes to coordinate diverse cellular events associated
with neuronal differentiation.
Wang et al. BMC Genomics 2013, 14:830 Page 12 of 16
http://www.biomedcentral.com/1471-2164/14/830complex contains chromatin modifiers is currently under
investigation.
Terminal cell differentiation is also tightly associated with
a global reduction in DNA damage repair activities
[1-3]. The underlying molecular mechanism is not well
understood. It has been reported that E1 ubiquitin-
activating enzyme can complement nucleotide-excision
repair deficiency in extracts from differentiated macro-
phages, suggesting a role of ubiquitination in the con-
trol of the DNA damage response during differentiation
[64]. Our study revealed that in HOXC9-induced neur-
onal differentiation, attenuation of the DNA damage re-
sponse resulted from global transcriptional repression
of DNA repair genes. This finding provides a molecular
mechanism for the long observed differentiation-induced
radiosensitivity in neuroblastoma cells [20,24-27]. For
HOXC9-induced differentiation, a total of 98 genes with
functions in the DNA damage response were significantly
downregulated. These genes are involved in all types
of DNA damage checkpoints and repair pathways. Import-
antly, we show that 32 of the 98 genes are direct tar-
gets of HOXC9. Thus, to a large extent, HOXC9
coordinates neuronal differentiation and attenuation of
DNA repair activities by simultaneously activating neuronal
genes and repressing DNA repair genes. Since the DNA
damage response and DNA replication machineries share
many components, we speculate that the downregulation
of DNA repair genes during differentiation is a conse-
quence of repression of cell cycle genes, particularly those
involved in DNA replication.
The stem cell model of cancer attributes cancer growth
to a subpopulation of cancer stem cells. It has been shown
recently that cancer stem cells are intrinsically resistant
to ionizing radiation and chemotherapy, as a result of
enhanced checkpoint activation and more effective DNAdamage repair [7-10]. Since differentiation is associated with
global downregulation of DNA repair activities, a combin-
ation of differentiation-inducing agents and irradiation or
chemotherapy may prove to be a more effective therapeutic
strategy for targeting cancer stem cells.
Conclusions
Using neuroblastoma cell differentiation as an experimen-
tal system, we delineate a molecular mechanism by which
HOXC9 coordinates diverse cellular processes associated
with differentiation by directly activating and repressing
the transcription of distinct sets of genes.
Methods
Cell culture and growth assays
The human neuroblastoma cell line BE(2)-C (CRL-2268,
ATCC) with Tet-Off inducible expression of myc-tagged
human HOXC9 has been described previously [18].
For E2F6 knockdown, BE(2)-C/Tet-Off/myc-HOXC9
cells were infected with lentiviruses expressing shRNA
against E2F6 (TRCN013819, E2F6sh-2, TTTCGAGT-
TAAATAAACCAGC; TRCN013821, E2F6sh-4, ATTG
GTGATGTCATACACTCT; TRCN018201, E2F6sh-6, ATC-
CAAAGCATCTTCCATTGC; Thermo Fisher Scientific).
Cells were cultured in a 1:1 mixture of DMEM and
Ham’s nutrient mixture F12 supplemented with 10%
fetal bovine serum (Invitrogen-Gibco) in the presence or
absence of doxycycline. Cells were examined and phase
contrast images captured using an Axio Observer micro-
scope and AxioVision software (Carl Zeiss MicroImaging),
and viable cell numbers were determined by trypan
blue exclusion assay. For cell cycle analysis, cells were
fixed in 70% ethanol, incubated with ribonuclease A
(Sigma-Aldrich), and stained with 20 μg/ml propidium
iodide (Invitrogen-Gibco). Samples were analyzed using
a FACSCalibur system and ModFitLT V3.2.1 software
(BD Bioscience).
Microarray gene expression profiling
Total RNA was isolated using Trizol (Invitrogen) from three
independent samples of BE(2)-C/Tet-Off/myc-HOXC9
cells cultured in the presence or absence of doxycycline
for 6 days. RNA was measured and quality assessed by a
NanoDrop spectrophotometer and an Agilent 2100
Bioanalyzer (Agilent Technologies). Affymetrix microarray
analysis was performed using the Human Gene 1.0 ST
microarray chip. Data were normalized, significance
determined by ANOVA, and fold change calculated
with the Partek Genomics Suite (Partek Inc.). Gene
annotation enrichment analysis was performed with
DAVID v6.7 [30], GSEA [65], and IPA (Ingenuity®
Systems www.ingenuity.com) for all significantly changed
genes (≥ +1.5 and ≤ −1.5 fold, P < 0.01).
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Two independent preparations of BE(2)-C/Tet-Off/
myc-HOXC9 cells cultured in the presence or absence
of doxycycline for 6 days were used for ChIP. Cross-linked
chromatin DNA was sheared through sonication and
immunoprecipitated using mouse anti-myc tag (clone 4A6,
Millipore) or mouse anti-E2F6 (sc-53273, Santa Cruz
Biotechnologies) according to the published procedure
[66]. For ChIP-seq, libraries were generated from ChIP
genomic DNA samples according to the Illumina
ChIP-seq library construction procedure, and sequenced
using Illumina Genome Analyzer IIx with a read length of
36 or 76 bp. For ChIP-qPCR, ChIP genomic DNA samples
were assayed in triplicate by PCR using an iQ5 real-time
PCR system (Bio-Rad) and the following primer sets that
cover the promoter regions of CCNB1 (CCNB1_2 and
CCNB1_6), CDCA8 (CDCA8_5P200 and CDCA8_5P1K),











Raw Illumina sequencing reads from the two independ-
ent ChIP replicates (rep1, GEO GSM848788 and rep2,
GEO GSM848789) in the FASTQ format were cleaned
using in-house scripts by trimming sequencing adaptors
and low quality bases in both ends (Q < 67 in Illumina 1.5).
Cleaned sequences were then mapped to the human
genome (hg19) using Novoalign v2.07 for identifying
the reads that were mapped uniquely to a single genomic
locus. The identified reads from the rep1 ChIP sample
(GEO GSM848788) were used for peak calling with
Model-based Analysis of ChIP-Seq (MACS v1.4) [67], and
only those peaks with FDR <1% were compared with
RefSeq genes in the UCSC genome browser and classified
into functional categories such as promoters, 5’-UTRs,
exons, introns, 3’-UTRs, downstream, and intergenic
regions. To measure the correlation of two HOXC9
replicates, we used 200 bp non-overlapping windows
where a tag density is defined as the number of reads
in a window. We calculated Pearson correlation coef-
ficient with R > 0.9 being highly correlated. For motif
analysis, we extracted 100 bp flanking sequences from
predicted peak summits and ran MEME for identify-
ing statistically overrepresented motifs. We performed
MAST to search motifs in the peaks using the model
built by MEME.Identification of HOXC9 target genes
Genes with HOXC9-binding peaks that are non-intergenic
(i.e., within −5 ~ +5 kb of genes) were defined as HOXC9
target genes. To correlate HOXC9 binding to gene expres-
sion, we combined the HOXC9 ChIP-seq data with the
HOXC9 microarray data using in-house scripts to
generate a list of the genes whose regulatory elements
are bound by HOXC9 and whose expression levels
are significantly changed (≥ +1.5 and ≤ −1.5 fold, P < 0.01)
as the result of HOXC9 induction. The significantly
up- and down-regulated HOXC9 target genes were
then subjected to gene annotation enrichment analysis
with DAVID v6.7, GSEA, and IPA.Immunoprecipitation and mass spectrometric analyses
BE(2)-C/Tet-Off/myc-HOXC9 cells were cultured in the
absence of doxycycline for 6 days and nuclear extracts were
prepared following the Dignam protocol [68] except that
buffer C contained 300 mM NaCl. Extracts from 1 × 107
cells were incubated with Protein A/G beads (Invitrogen)
coated with 4 μg mouse anti-Myc tag (clone 4A6, Millipore)
or mouse IgG for overnight at 4°C. The beads were washed
3 times with buffer C containing 150 mM NaCl, dried in a
SpeedVac, re-suspended in a buffer containing 8M urea,
5 mM DTT and 100 mM ammonium bicarbonate, and
alkylated with 15 mM iodoacetamide for 1 hour. After
alkylation, unreacted iodoacetamide was removed by
15 mM DTT and the urea concentration was diluted
to ~1M with a buffer containing 50 mM ammonium
bicarbonate and 2 mM CaCl2. Immunoprecipitated pro-
teins were digested with 14 ng/μl sequencing grade
trypsin (Promega) for 24 hours at 37°C. The digests
were desalted with a Micro Trap desalting cartridge
(Michrom BioResources), and tryptic peptides eluted
with LC-MS Solvent B (90/10/0.05%: Acetonitrile/water/
heptafluorobutyric acid) and dried in a SpeedVac. The
digests were analyzed by Nano-HPLC using a Nano Trap
column (CL5/61241/00, Michrom BioResources) and an
Agilent 1200 Series Nano pump (Agilent Technologies)
equipped with a refrigerated autosampler. An Agilent 1200
Series Capillary LC loading pump was used to introduce the
sample onto a Captrap cartridge for sample concentration
and de-salting.
Data-dependent MS and MS/MS spectra were acquired
on an LTQ Orbitrap Discovery (Thermo Fisher Scientific)
using 2 micro-scans, with a maximum injection time of
200 ms with 2 Da peak isolation width. Six scan events
were recorded for each data acquisition cycle. The first
scan event, acquired by the FTMS, was used for full scan
MS acquisition from 300–2000m/z. Data were recorded
in the Centroid mode only. The remaining five scan
events were used for collisionally activated dissociation
(CAD): the five most abundant ions in each peptide MS
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mass spectra.
Database searching and protein identification
All MS/MS data were analyzed using BioWorks Rev.3.3.1
SP1 (Thermo Fisher Scientific) and X!Tandem (thegpm.
org). SEQUEST was set up to search NCBInr_Homosa-
piens_05262011.fasta (221863 entries) and the human.pro-
tein_RefSeq_01192012 database (33376), and X!Tandem
was set up to search subsets of the databases. SEQUEST
and X!Tandem were searched with a fragment ion mass
tolerance of 0.80 Da and a parent ion tolerance of 10.0
PPM. Scaffold (Proteome Software) was used to validate
MS/MS-based peptide and protein identifications. Peptide
identifications were accepted if they could be established
at greater than 95.0% probability as specified by the Pep-
tide Prophet algorithm [69]. Protein identifications were
accepted if they could be established at greater than 90.0%
probability and contained at least 1 identified peptide.
Protein probabilities were assigned by the Protein Prophet
algorithm [70]. Proteins that contained similar peptides
and could not be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony.
Single-peptide protein identification was accepted only
if the protein was independently identified by both
SEQUEST and X!Tandem.
Size-exclusion chromatography
Size-exclusion chromatography was performed with a
Superose-6 10/300 GL column (24 ml bed volume) and
an AKTA purifier (GE Healthcare). Nuclear extracts
(0.5 ml) were loaded onto the column equilibrated with
PBS, and 0.5 ml fractions were collected and analyzed.
Co-immunoprecipitation
Nuclear extracts or pooled Sepharose-6 fractions were
incubated with protein A/G beads coated with mouse
anti-Myc tag (clone 4A6), mouse anti-E2F6, or control
mouse IgG for 2 hours at 4°C. After washing 3 times
with PBS, the beads were suspended in standard SDS
sample buffer and analyzed by immunoblotting.
Immunoblotting
Unless indicated, all antibodies were from Santa Cruz
Biotechnologies. Samples were suspended in SDS sample
buffer and boiled. Proteins were separated on SDS-
polyacrylamide gels, transferred to nitrocellulose mem-
branes, and probed with the following primary antibodies:
rabbit anti-cyclin A2 (sc-751, 1:200), rabbit anti-cyclin B1
(sc-752, 1:200), mouse anti-myc-tag (9E10, hybridoma
supernatant, 1:10), rabbit anti-E2F6 (sc-22823, 1:200),
mouse anti-MEIS2 (63-T, sc-81986, 1:400), mouse anti-
NEFM (NF-09, sc-51683, 1:200), and rabbit anti-β-
actin (600-401-886, Rockland Immunochemicals, 1:2000).Horseradish peroxidase-conjugated goat anti-mouse and
goat anti-rabbit IgG were used as secondary antibodies.
Proteins were visualized using a SuperSignal West Pico
chemiluminescence kit (Pierce, Thermo Fisher Scientific)
and quantified with ImageJ (National Institutes of Health).
For visualization and quantification with the Odyssey
system, goat anti-mouse IRDye 800, anti-rabbit IRDye
800, anti-mouse IRDye 680, and anti-rabbit IRDye 680
were used as secondary antibodies (LI-COR Biosciences).Statistics
All quantitative data were analyzed and presented with
GraphPad Prism 5.0f for Mac using unpaired, two-tailed
Student’s t-test.Additional files
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